Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

NF2 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

NF2 mutation	Breast Cancer	NF2 mutation	Breast Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
NF2 mutation	Thyroid Gland Anaplastic Carcinoma	NF2 mutation	Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3
NF2 mutation	Renal Cell Carcinoma	NF2 mutation	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: C3 – Early Trials nivolumab + cabozantinib tablet Sensitive : C3	nivolumab + cabozantinib tablet Sensitive: C3 – Early Trials nivolumab + cabozantinib tablet Sensitive : C3
NF2 mutation	Meningioma	NF2 mutation	Meningioma	GSK2256098 Sensitive: C3 – Early Trials GSK2256098 Sensitive : C3	GSK2256098 Sensitive: C3 – Early Trials GSK2256098 Sensitive : C3
NF2 mutation	Kidney Medullary Carcinoma	NF2 mutation	Kidney Medullary Carcinoma	bevacizumab + erlotinib Sensitive: C4 – Case Studies bevacizumab + erlotinib Sensitive : C4	bevacizumab + erlotinib Sensitive: C4 – Case Studies bevacizumab + erlotinib Sensitive : C4
NF2 mutation	Mesothelioma	NF2 mutation	Mesothelioma	CBL0102 Sensitive: D – Preclinical CBL0102 Sensitive : D	CBL0102 Sensitive: D – Preclinical CBL0102 Sensitive : D
NF2 mutation	Mesothelioma	NF2 mutation	Mesothelioma	verteporfin Sensitive: D – Preclinical verteporfin Sensitive : D	verteporfin Sensitive: D – Preclinical verteporfin Sensitive : D